Inhibition of Experimental Neointimal

Anticoagulation and Thrombosis
Activated partial thromboplastin times were measured in animals before surgery and at 7 and 14 days. Continuous intravenous heparin infusion prolonged the aPTT to at least two times control in each animal at 7 and 14 days. There was no prolongation of the aPTT by either perivascular or stent-released heparin in any animal at any time point.
Complete thrombosis at 14 days was observed in 42% of the arteries in animals receiving a single intravenous bolus of heparin at the time of stent placement and oral aspirin continuously (see Table and Fig 2) . All forms of heparin administration reduced thrombosis in stentbearing arteries. Only 8% of arteries implanted with stents releasing heparin demonstrated complete thrombosis (P<.004), whereas heparin delivered either intravenously or into the perivascular space completely eliminated occlusive thrombosis (see Table and Table) .
Neointimal Hyperplasia
We compared heparin modulation of the arterial response to acute injury (balloon withdrawal with endothelial denudation) with the effect of heparin on the more chronic and severe injury imposed by the placement of metal stents within denuded arteries. Fourteen days after balloon injury alone, a highly cellular neointima had formed, separating the internal elastic lamina from the lumen. Intimal cross-sectional area was 0.26±0.03 mm2 (see Table and Fig 3) . Heparin after balloon injury was equally effective at inhibiting neointimal hyperplasia whether delivered via continuous intravenous infusion for 14 days or via controlled perivascular release from EVAc matrices providing local delivery of much lower doses primarily for the first 3 days (see Table and Quantification of the extent of deep vessel injury33 revealed an injury score of 0.56±0.07 in arterial sections from control animals receiving stents but not postprocedure heparin. There was no significant difference between the control group and any heparin-treated group (Table) . Discussion Heparin inhibited thrombosis regardless of the method of delivery and neointimal hyperplasia irrespective of the type of arterial injury, but the reduction in the intimal response after more severe and chronic injury elicited by endovascular stents was attained only with prolonged heparin delivery continuing for the duration of the experiment. Small doses of heparin released into the perivascular space primarily for the first 3 days after stent placement or at the arterial lumen reduced thrombosis but had little effect on neointimal hyperplasia, whereas heparin delivered via continuous FIG 5 . Photomicrographs of rabbit iliac arterial cross sections 14 days after balloon withdrawal denudation followed by endovascular stent placement. A, Control; B, receiving continuous intravenous heparin; C, receiving heparin releasedfrom the stent itself; D, receiving heparin delivered into the perivascular space for the first 3 days after injury; or E, receiving heparin delivered into the perivascular space continuously for 14 days. Neointimal hyperplasia separates the stent wires (black rectangles) and internal elastic laminae (arrows) from the lumina. Open space around wires is an artifact of sectioning. Original magnification x400; stained with Verhoeffs tissue elastin stain.
intravenous infusion or continuous local perivascular release reduced stent-induced neointimal hyperplasia by 64% and 54%, respectively.
In arteries subjected to a single superficial acute injury (balloon withdrawal denudation), deep mural injury was less common and neointimal hyperplasia was fourfold less extensive than after stent placement. Local perivascular delivery of heparin primarily over the first 3 days after single acute vascular injury was as effective as continuous intravenous heparin for 14 days (reducing neointimal area by 54% and 57%, respectively). These data confirm an earlier report that after rat carotid artery denudation, 3 or 7 days of intravenous heparin reduced SMC growth fraction, migration, and accumulation as effectively as more prolonged administration. 34 In contrast, our data show that after endovascular stent placement, 3 The results in this study further highlight the divergence of human atherosclerosis and restenosis from animal models of acute arterial injury. The clinical failure of agents antiproliferative in some animal models may reflect differences in the extent of injury and/or differences between an otherwise normal, acutely injured blood vessel and an atherosclerotic vessel subjected to angioplasty or other manipulation. The transition from tissue culture and animal studies to human trials may be enhanced by further elucidation of the biological mechanisms that determine growth after severe or prolonged vascular insults.
Study Limitations
The site, duration, and amount of heparin delivered dictated the drug's modulation of thrombosis and neointimal hyperplasia after superficial acute or deeper chronic injury. We have not yet measured or localized the deposition of exogenous heparin within the arterial wall or correlated the distribution of drug with its biological effects. Measurement and localization of heparin in vivo are difficult because of heparin's high solubility and rapid degradation into smaller oligomers of varying biological activities. These issues are undergoing active investigation in our laboratory. The amount of heparin delivered from stents was small although adequate to reduce thrombosis: Stent-based heparin release provided only 2% the dose of heparin provided by perivascular matrix-based heparin delivery. The delivery of higher doses for longer periods of time might produce different results.
Future Directions
The accurate transition from experimental models of vascular injury to clinical reduction in accelerated arteriopathies may be limited by differences in the biology of animal models and human disease, differential responses of various components of vascular repair, and dissimilarities between human atherosclerotic arteries and normal vessels of the laboratory animal. We believe that an additional explanation may lie in the methods used to deliver agents and in the failure of clinical trials to adequately extrapolate experimental tissue culture and animal data to human use, rendering the broad application of negative conclusions from such clinical trials unwarranted. The extent of experimental neointimal hyperplasia and the response to an antiproliferative agent, heparin, differs significantly between arteries subjected to a single acute injury and arteries subjected to more prolonged and severe injury. The latter model may be more akin to clinical coronary arterial instrumentation, characterized by deep intimal and medial disruption. Future clinical studies of experimentally effective antiproliferative therapies will need to address duration and degree of drug-tissue interaction in light of the duration and degree of the vascular response to injury before such compounds are deemed ineffective at limiting human restenosis.
